PT  - JOURNAL ARTICLE
AU  - Nunes, José Pedro L.
TI  - Mortality and use of angiotensin converting enzyme inhibitors in Covid 19 disease – a systematic review
AID  - 10.1101/2020.05.29.20116483
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.29.20116483
4099  - http://medrxiv.org/content/early/2020/07/07/2020.05.29.20116483.short
4100  - http://medrxiv.org/content/early/2020/07/07/2020.05.29.20116483.full
AB  - Background Interest exits concerning the use of angiotensin converting enzyme inhibitors (ACEi) in patients with Covid-19 disease.Objectives To perform a systematic review on mortality associated to the use of ACEi in patients with Covid 19 disease.Methods Search in Medline (PubMed), in ISI Web of Knowledge and in medRxiv database; use of other sources.Results A total of 33 articles were evaluated. Concerning the papers used to produce the meta-analyses, seven studies were selected, five of which were used. These five studies involved a total number of 944 patients treated with ACEi and 5173 not treated with ACEi. Increased mortality was seen in association to the use of ACEi in the context of Covid-19 disease (ACEi users versus non-users; odds ratio, 1.48; 95% confidence interval [CI], 1.02 to 2.15; P=0.04). When compared to mortality in patients treated with angiotensin receptor blockers, mortality of patients treated with ACEi was not significantly different (odds ratio, 0.96; 95% confidence interval [CI], 0.76 to 1.21; P=0.74). Concerning the remaining reports, different types of data adjustments were used by several authors, after which increased mortality was not seen in association to the use of ACEi in this context.Conclusions ACEi use could act as a marker of increased mortality risk in some but not all Covid-19 disease settings. The data now presented do not prove a causal relation but argue in favor of carrying out clinical trials studying ACEi in Covid-19 patients, in order to establish the safety of ACEi use in this context.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding received for the preparation of the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The author states that no patients were involved. The author states that this paper has no connection to any clinical trial. The author states that he has followed all appropriate reporting guidelines.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data was obtained from the cited articles